Merck Names Siren Biotechnology As North American Advance Biotech Grant Winner
MilliporeSigma Announces Siren Biotechnology as Winner of its North American Advance Biotech Grant
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., which was recently acquired by Novo Holdings, have entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)
Epigenetic editing in primates. Cytokine-expressing AAVs for glioma. Gene therapy for the heart. These were just some of the dozens of preclinical advances shared at the American Society for Gene and Cell Therapy’s 2023 annual meeting, held May 16 through May 20 in Los Angeles.
Just before noon on May 17 at the American Society for Gene and Cell Therapy’s annual meeting, a young, buzzing crowd filled a small conference room at the Los Angeles Convention Center for a special lunch session. Snapshots of the host company’s staff embarking on outdoor adventures rolled across the projector screen to the tune of upbeat pop music blaring from loudspeakers.
Novel approach combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single transformative modalityBelieved to be the first ever AAV...
Data demonstrated that AAV vectors expressing engineered immunomodulatory interferon (IFN) cytokine payloads led to: Rapid and selective reduction in tumor size in high-grade glioma (HGG)...